LitAlert ~~

    • Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells.
    • Eskiler GG, Ozturk M.
    • Cell Signal. 2021 Dec 24:110229. doi: 10.1016/j.cellsig.2021.110229. Epub ahead of print.
    • Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer.
    • Yordanova M, Hubert A, Hassan S.
    • Pharmaceuticals (Basel). 2021 Dec 6;14(12):1270. doi: 10.3390/ph14121270.